| 50.97 1.059 (2.12%) | 07-17 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 64.18 | 1-year : | 74.96 |
| Resists | First : | 54.95 | Second : | 64.18 |
| Pivot price | 52.34  |
|||
| Supports | First : | 46.17 |
Second : | 40.75 |
| MAs | MA(5) : | 51.14 |
MA(20) : | 51.28 |
| MA(100) : | 44.67 |
MA(250) : | 36.8 |
|
| MACD | MACD : | 1.6 |
Signal : | 2.1 |
| %K %D | K(14,3) : | 32.3 |
D(3) : | 42.2 |
| RSI | RSI(14): 55 |
|||
| 52-week | High : | 54.95 | Low : | 20.52 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ BBC ] has closed above bottom band by 23.4%. Bollinger Bands are 17.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 51.45 - 51.69 | 51.69 - 51.92 |
| Low: | 48.49 - 48.76 | 48.76 - 49.02 |
| Close: | 50.51 - 50.95 | 50.95 - 51.36 |
This exchange-traded fund (ETF) endeavors to match the capital appreciation and income generation of the LifeSci Biotechnology Clinical Trials Index, disregarding fees and expenses. The underlying index focuses on tracking the financial progress of a carefully chosen group of biotechnology firms engaged in clinical trials. It is important to note that, as of February 27, the fund's official name transitioned from Virtus LifeSci Biotech Clinical Trials ETF to Virtus Biotech Clinical Trials ETF.
Fri, 17 Jul 2026
Trading the Move, Not the Narrative: (BBC) Edition - Stock Traders Daily
Tue, 30 Jun 2026
Biotech ETF (BBC) Touches a New 52-Week High - Yahoo Finance
Sat, 13 Jun 2026
Price-Driven Insight from (BBC) for Rule-Based Strategy - Stock Traders Daily
Fri, 10 Apr 2026
Biotech ETF (BBC) Touches Fresh 52-Week High - Yahoo Finance
Tue, 14 Mar 2023
The 5 Best Biotech ETFs of 2024 - ETF.com
Tue, 31 Dec 2019
15 Best Performing ETFs of 2019 - ETF Trends
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
AMEX
|
|
|
Sector:
Financial Services
|
|
|
Industry:
Asset Management
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|